Nabil Andrawis, MD
Internal Medicine · Burke, VANPI 1356310551
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $11,560 of the $14,115 with a category attached, or 81.9%. 9 manufacturers reported payments, led by Eli Lilly at 47.9% of the total. Reporting peaked in 2019 at $6,845 and has fallen 68.3% since, to $2,170 in 2025. Among internal medicine clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 31 payments — averaging $455.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$7K
- Janssen Global Services, LLC$4K
- Novo Nordisk$2K
- Boehringer Ingelheim International GmbH$1K
- AstraZeneca$46
- Exact Sciences$40
- plus $72 from 3 others
Across 903 payments — averaging $9463.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$1.6M
- Pfizer$1.3M
- Eli Lilly$1.2M
- Boehringer Ingelheim$805K
- AbbVie$720K
- Sanofi US Services Inc.$603K
- plus $2.4M from 20 others
What the payments were for
- Consulting fees$11,56082%
- Travel & lodging$1,60211%
- Food & beverage$9537%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 6 | $6,756 |
| Janssen Global Services, LLC | 3 | $3,805 |
| Novo Nordisk | 3 | $2,152 |
| Boehringer Ingelheim International GmbH | 12 | $1,244 |
| AstraZeneca | 1 | $46 |
| Exact Sciences | 2 | $40 |
| Novartis | 2 | $29 |
| Boehringer Ingelheim | 1 | $22 |
| Pfizer | 1 | $20 |
How this compares
$14,115 in reported general payments places this provider in the 95th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 26 | $156 |
| Metformin Hcl | 14 | $123 |
| Lisinopril | 11 | $71 |
| Methimazole | 11 | $71 |
| Amlodipine Besylate | 17 | $52 |
| Simvastatin | 12 | $48 |
| Losartan Potassium | 11 | $43 |
| Hydrochlorothiazide | 16 | $31 |
| Atenolol | 12 | $24 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Burke
- Kumar AbhishekMechanicsville$1M
- Amit MahajanFalls Church$1M
- Kevin DonohueFalls Church$655K
- Denise BrunerArlington$227K
- Anjali KaloreMidlothian$215K
- Scott GerrishVienna$207K
- Lawrence SchwartzRichmond$205K
- Wally SmithRichmond$177K
- Gautam GulatiMc Lean$136K
- Francesse BatailleDumfries$109K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.